William Blair Upgrades Larimar Therapeutics (LRMR) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Larimar Therapeutics (LRMR) CEO and CFO Buy Stock in Recent Offering
September 19, 2022 8:10 AM EDTLarimar Therapeutics (NASDAQ: LRMR) sees a couple of insider buys. Shares were purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on September 16, 2022.
CEO, Carole Ben-Maimon, bought 31,746 shares on 09/16/22 at $3.15CFO, Michael Celano, bought 31,746 shares on 09/16/22 at $3.15... More